Chemotherapy for advanced gastric cancer: Across the years for a standard of care

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 6, 2007, Pages 797-808

  Scartozi, Mario ^a   Galizia, Eva ^a   Verdecchia, Lorena ^a   Berardi, Rossana ^a   Antognoli, Stefania ^a   Chiorrini, Silvia ^a   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Chemotherapy; Gastric cancer; Palliation; Survival

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; IRINOTECAN; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; TRASTUZUMAB;

ADVANCED CANCER; ALOPECIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LEUKOPENIA; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; REVIEW; STANDARD; STOMACH CANCER; STOMATITIS; SYMPTOM; SYSTEMATIC REVIEW; THROMBOEMBOLISM; DISEASE FREE SURVIVAL; MORTALITY; PATIENT CARE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; STOMACH TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DISEASE-FREE SURVIVAL; HUMANS; PATIENT CARE; STOMACH NEOPLASMS;

EID: 34247844625     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.6.797     Document Type: Review

References (77)

1. JEMAL A, SIEGEL R, WARD E et al.: Cancer statistics (2006). CA Cancer J. Clin. (2006) 56:106-130.
2. NITTI D, MARCHET A, OLIVIERI M et al.: Lymphadenectomy in patients with gastric cancer a critical review. Tumori (2003) 2:S35-S38.
3. BOUVIER AM, HAAS O, PIARD F et al.: How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer (2002) 94:2862-2866.
4. AJANI JA: Evolving Chemotherapy for Advanced Gastric Cancer. Oncologist (2005) 10:49-58.
5. WOHRER SS, RADERER M, HEJNA M: Palliative chemotherapy for advanced gastric cancer. Ann. Oncol. (2004) 15:1585-1595.
6. OHTSU A, SHIMADA Y, SHIRAO K et al.: Randomized Phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J. Clin. Oncol. (2003) 21:54-59.
7. MACDONALD JS, SCHEIN PS, WOOLLEY PV et al.: 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann. Intern. Med. (1980) 93:533-536.
8. DOUGLASS HO JR, LAVIN PT, GOUDSMIT A et al.: An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J. Clin. Oncol. (1984) 2:1372-1381.
9. GASTROINTESTINAL TUMOR STUDY GROUP: Triazinate and platinum efficacy in combination with 5-fluorouracil and doxorubicin: results of a three-arm randomized trial in metastatic gastric cancer. Gastrointestinal Tumor Study Group. J. Natl. Cancer. Inst. (1988) 80:1011-1015.
10. GASTROINTESTINAL TUMOR STUDY GROUP: A comparative clinical assessment of combination chemotherapy in the management of advanced gastric carcinoma: the Gastrointestinal Tumor study Group. Cancer (1982) 49:1362-1366.
11. LACAVE A, WILS J, BLEIBERG H et al.: An EORTC Gastrointestinal Group Phase III evaluation of combinations of methyl-CCNU, 5-fluorouracil, and adriamycin in advanced gastric cancer. J. Clin. Oncol. (1987) 5:1387-1393.
12. CULLINAN SA, MOERTEL CG, FLEMING TR et al.: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil versus fluorouracil and doxorubicin versus fluorouracil, doxorubicin, and mitomycin. JAMA (1985) 253:2061-2067.
13. KLEIN HO, WICKRAMANAYAKE PD, DIETERLE F et al.: MTX/5-FU and adriamycin for gastric cancer. Semin. Oncol. (1983) 10:29-31.
14. WILS JA, KLEIN HO, WAGENER DJ et al.: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J. Clin. Oncol. (1991) 9:827-831.
15. PREUSSER P, WILKE H, ACHTERRATH W et al.: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J. Clin. Oncol. (1989) 7:1310-1317.
16. KELSEN D, ATIQ OT, SALTZ L et al.: FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J. Clin. Oncol. (1992) 10:541-548.
17. DIAZ-RUBIO E, JIMENO J, ARANDA E et al.: Etoposide (E) +epirubicin (E) + cisplatin (P) combination chemotherapy (EEP) in advanced gastric cancer: negative impact on clinical outcome. Spanish Cooperative Group for GI Tumor Therapy (T.T.D.). Ann. Oncol. (1992) 3:861-863.
18. MURAD AM, SANTIAGO FF, PETROIANU A et al.: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer (1993) 72:37-41.
19. PYRHONEN S, KUITUNEN T, NYANDOTO P et al.: Randomised comparison of fluorouracil, pidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br. J. Cancer (1995) 71:587-591.
20. SCHIPPER DL, WAGWNWR DJ: Chemotherapy of gastric cancer. Anticancer Drugs (1996) 7:137-149.
21. GLIMELIUS B, EKSTROM K, HOFFMAN K et al.: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol. (1997) 8:163-168.
22. FINDLAY M, CUNNINGHAM D, NORMAN A et al.: A Phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann. Oncol. (1994) 5:609-616.
23. ZANIBONI A, BARNI S, LABIANCA R et al.: Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report. Cancer (1995) 76:1694-1699.
24. COCCONI G, BELLA M, ZIRONI S et al.: Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J. Clin. Oncol. (1994) 12:2687-2693.
25. COCCONI G, CARLINI P, GAMBONI A et al.: Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann. Oncol. (2003) 14:1258-1263.
26. CASCINU S, LABIANCA R, ALESSANDRONI P et al.: Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J. Clin. Oncol. (1997) 15(11):3313-3319.
27. WEBB A, CUNNINGHAM D, SCARFFE JH et al.: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. (1997) 15:261-267.
28. KIM NK, PARK YS, HEO DS et al.: A Phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer (1993) 71:3813-3818.
29. ICLI F, CELIK I, AYKAN F et al.: A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Cancer (1998) 83:2475-2480.
30. VANHOEFER U, ROUGIER P, WILKE H et al.: Final results of a randomized Phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J. Clin. Oncol. (2000) 18:2648-2657.
31. ROSS P, NICOLSON M, CUNNINGHAM D et al.: Prospective randomized trial of comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J. Clin. Oncol. (2002) 20:1996-2004.
32. MURAD AM, PETROIANU A, GUIMARAES RC et al.: Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am. J. Clin. Oncol. (1999) 22:580-586.
33. KIM YH, SHIN SW, KIM BS et al.: Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer (1999) 85:295-301.
34. KOLLMANNSBERGER C, QUIETZSCH D, HAAG C et al.: A Phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br. J. Cancer (2000) 83:458-462.
35. RYOO B, KIM T, CHOI S et al.: A Phase II trial of paclitaxel (T) and carboplatin (C) for advanced gastric cancer refractory to 5-fluorouracil (F) and cisplatin/heptaplin (P). Proc. Am. Soc. Clin. Oncol. (2001) 20:28b.
36. HONECKER F, KOLLMANNSBERGER C, QUIETZSCH D et al.: Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticncer Drugs (2002) 13:497-503.
37. GADGEEL SM, SHIELDS AF, HEILBRUN LK et al.: Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am. J. Clin. Oncol. (2003) 26:37-41.
38. KETTNER E, RIDWELSKI K, KEILHOLZ U et al.: Docetaxel and cisplatin combination chemotherapy for advanced gastric cancer: results of two Phase II studies. Proc. Am. Soc. Clin. Oncol. (2001) 20:657a.
39. RIDWELSKI K, GEBAUER T, FAHLKE J et al.: Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann. Oncol. (2001) 12:47-51.
40. HAWKINS R, CUNNINGHAM D, SOERBYE H et al.: Randomized Phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC). Proc. Am. Soc. Clin. Oncol. (2003) 22:257.
41. PARK SH, KANG WK, LEE HR et al.: Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen. Am. J. Clin. Oncol. (2004) 27:477-480.
42. ROTH AD, MAILBACH R, FALK S et al.: Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized Phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J. Clin. Oncol. (2004) 22:318s.
43. AJANI JA, FODOR MB, TJULANDIN SA et al.: Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J. Clin. Oncol. (2005) 23:5660-5667.
44. THUSS-PATIENCE PC, KRETZSCHMAR A, REPP M et al.: Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized Phase II study. J. Clin. Oncol. (2005) 23:494-501.
45. KIM H, PARK JH, BANG SJ et al.: A Phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment. Jpn. J. Clin. Oncol. (2005) 35:727-732.
46. PARK SR, CHUN JH, KIM YW et al.: Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma. Am. J. Clin. Oncol. (2005) 28:433-438.
47. JEUNG HC, RHA SY, KIM YT, NOH SH, ROH JK, CHUNG HC: A Phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer. Oncology (2006) 70:63-70.
48. VAN CUTSEM E, MOISEYENKO VM, TJULANDIN S et al.: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol. (2006) 24:4991-4997.
49. LOUVET C, ANDRE T, TIGAUD JM et al.: Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J. Clin. Oncol. (2002) 20:4543-4548.
50. DE VITA F, ORDITURA M, MATANO E et al.: A Phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br. J. Cancer (2005) 92:1644-1649.
51. LORDICK F, LORENZEN S, STOLLFUSS J et al.: Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br. J. Cancer (2005) 93:190-194.
52. AL-BATRAN S, HARTMANN J, PROBST S et al.: A randomized Phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP). Proc. Am. Soc. Clin. Oncol. (2006) Abstr. LBA4016.
53. DI BARTOLOMEO M, BAJETTA E, SOMMA L et al.: Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients. Oncology (1996) 53:54-57.
54. PARK YH, RYOO BY, CHOI SJ et al.: A Phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br. J. Cancer (2004) 90:1329-1333.
55. PARK YH, KIM BS, RYOO BY, YANG SH: A Phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br. J Cancer (2006) 94(7):959-963.
56. ORDITURA M, MARTINELLI E, GALIZIA G et al.: Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a Phase II study. Ann. Oncol. (2006) 1710:1529-1532.
57. GIORDANO KF, JATOI A, STELLA PJ et al.: Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a Phase II study from the North Central Cancer Treatment Group. Ann. Oncol. (2006) 17:652-656.
58. KIM JG, SOHN SK, KIM DH et al.: Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology (2005) 68:190-195.
59. LORENZEN S, DUYSTER J, LERSCH C et al.: Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a Phase II trial. Br. J. Cancer (2005) 92:2129-2133.
60. CHUN JH, KIM HK, LEE JS et al.: Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am. J. Clin. Oncol. (2005) 28:188-194.
61. KANG Y, KANG WK, SHIN DB et al.: Randomized Phase III trial of capecitabine/cisplatin (XP) versus continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results. Proc. Am. Soc. Clin. Oncol. (2006) Abstr. LBA4018.
62. CUNNINGHAM MD, RAO S, STARLING N et al.: Randomised multicentre Phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: the REAL 2 trial. NCRI Upper GI Study Group. Proc. Am. Soc. Clin. Oncol. (2006) Abstr. LBA4017 D.
63. BOKU N, OHTSU A, SHIMADA Y et al.: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J. Clin. Oncol. (1999) 17:319-323.
64. SOUGLAKOS J, SYRIGOS K, POTAMIANOU A et al.: Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicenter Phase II trial. Ann. Oncol. (2004) 15:1204-1209.
65. POZZO C, BARONE C, SZANTO J et al.: Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized Phase II study. Ann. Oncol. (2004) 15:1773-1781.
66. BOUCHE O, RAOUL JL, BONNETAIN F et al.: Randomized multicenter Phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplarin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J. Clin. Oncol. (2004) 22:4319-4328.
67. YILMAZ U, OZTOP I, ALACACIOGLU A et al.: Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy. Br. J. Cancer (2006) 94(7):959-963.
68. DANK M, ZALUSKI J, BARONE C et al.: Randomized Phase III trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) versus CDDP + 5FU in 1st-line advanced gastric cancer patients. J. Clin. Oncol. (2005) 23:308s.
69. WOELL E, KÜHR T, EISTERER W et al.: Oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. Final results of a multicenter Phase II trial. Proc. Am. Soc. Clin. Oncol. (2006) Abstr. 4070.
70. LEE J, KANG W, LEE S et al.: A Phase II study of ironotecan, oxaliplatin, 5 fluorouracil, leucovorin (FOLFOXIRI) as a first-line chemotherapy in metastatic gastric cancer. Proc. Am. Soc. Clin. Oncol. (2006) Abstr. 4076.
71. BAEK J, KIM J, CHAE Y et al.: Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Proc. Am. Soc. Clin. Oncol. (2006) Abstr. 14037.
72. ENZINGER PC, FIDIAS P, MEYERHARDT J et al.: Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. ASCO Gastrointestinal Cancer Symposium. California, USA (26 - 28 January 2006) 68.
73. SHAH MA, RAMANATHAN RK, ILSON DH et al.: Multicenter Phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J. Clin. Oncol. (2006) 24:5201-5206.
74. PINTO C, DIFABIO F, SIENA S et al.: Phase II study of cetuximab in combination with FOLFIRI as first-line treatment in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): preliminary results. ASCO Gastrointestinal Cancer Symposium. California, USA (26 - 28 January 2006) 65.
75. WAGNER AD, GROTHE W, HAERTING J, KLEBER G, GROTHEY A, FLEIG WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. (2006) 24:2903-2909.
76. DRAGOVICH T, MCCOY S, FENOGLIO-PREISER CM et al.: Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J. Clin. Oncol. (2006) 24:4922-4927.
77. BECKER JC, MÜLLER-TIDOW C, SERVE H, DOMSCHKE W, POHLE T: Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World. J. Gastroenterol. (2006) 12(21):3297-3305.